Effects of Empagliflozin in chronic kidney disease on hemodialysis patients
Abstract
Abstract Background: Several risk factors in chronic kidney disease (CKD) patients cause mortality; cardiovascular risk is the most important one. So, new protective treatments have to be added to the management of CKD patients; the most important one are renin angiotensin aldosterone system inhibitors (RAASI), but the latest one are sodium glucose transporter 2 inhibitors (SGLT2i). Here in this study, we tried to approve cardiac and hematologic benefits of Empagliflozine using in end stage renal disease (ESRD) on renal replacement therapy (RRT) patients.
Methods:: we started Empagliflozin 10 mg for 9 months in 17 hemodialysis patients. Echocardiography and serum hemoglobin to measure cardiac parameters (interventricular septum diameter {IVSD} and ejection fraction{EF%}) and serum hemoglobin (HG) levels were done at baseline and after 9 months. We included diabetic and non-diabetic patients in our study. Patients with urinary anomalies were excluded. Statistical analysis was done to the results by IBM SPSS program to evaluate the benefits.
Results:: We included 17 participants, 64.7 % of them were male and 35.3% were female. There ages ranges from 22 years old to 75. Results declared cardiac benefits, as interventricular septum diameter(IVSD) was reduced by mean of 0.08 cm (p.value 0.002), (Std.Deviation(0.088), and increased left ventricular ejection fraction (EF%) by mean of 2.7 % after treatment. (p.value 0.15), (Std.Deviation (7.48), and hematologic benefits, as…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.